“The biggest question that arose from this is, ‘Why is there such a lack of large familial genetic disorder epidemiological studies?’ says Laura Bukavina, MD, MPH.
In this video, Laura Bukavina, MD, MPH, and Sarah P. Psutka, MD, MS, discuss the questions raised by the European Urology study, “Epidemiology of Renal Cell Carcinoma: 2022 Update.” Bukavina is a urologic oncology fellow at Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Psutka is an associate professor of urology at University of Washington Medical Center, Seattle.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.
Toripalimab plus axitinib approved in China for renal cell carcinoma
April 11th 2024The approval is based on findings from the phase 3 RENOTORCH trial, which showed that toripalimab plus axitinib prolonged progression-free survival and improved the objective response rate in patients with advanced RCC compared with sunitinib.